JP2015533801A - イソキサゾリジン誘導体 - Google Patents

イソキサゾリジン誘導体 Download PDF

Info

Publication number
JP2015533801A
JP2015533801A JP2015531511A JP2015531511A JP2015533801A JP 2015533801 A JP2015533801 A JP 2015533801A JP 2015531511 A JP2015531511 A JP 2015531511A JP 2015531511 A JP2015531511 A JP 2015531511A JP 2015533801 A JP2015533801 A JP 2015533801A
Authority
JP
Japan
Prior art keywords
oxo
dimethyl
phenyl
pentaleno
tetradecahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015531511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533801A5 (enExample
Inventor
エレオノーラ ギディニ、
エレオノーラ ギディニ、
Original Assignee
シエシー ファルマセウティチィ ソシエタ ペル アチオニ
シエシー ファルマセウティチィ ソシエタ ペル アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47044778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015533801(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シエシー ファルマセウティチィ ソシエタ ペル アチオニ, シエシー ファルマセウティチィ ソシエタ ペル アチオニ filed Critical シエシー ファルマセウティチィ ソシエタ ペル アチオニ
Publication of JP2015533801A publication Critical patent/JP2015533801A/ja
Publication of JP2015533801A5 publication Critical patent/JP2015533801A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0068—Nitrogen and oxygen at position 16(17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2015531511A 2012-09-13 2013-08-23 イソキサゾリジン誘導体 Pending JP2015533801A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12184286 2012-09-13
EP12184286.8 2012-09-13
PCT/EP2013/067509 WO2014040837A1 (en) 2012-09-13 2013-08-23 Isoxazolidine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018109262A Division JP6736607B2 (ja) 2012-09-13 2018-06-07 イソキサゾリジン誘導体

Publications (2)

Publication Number Publication Date
JP2015533801A true JP2015533801A (ja) 2015-11-26
JP2015533801A5 JP2015533801A5 (enExample) 2018-03-01

Family

ID=47044778

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015531511A Pending JP2015533801A (ja) 2012-09-13 2013-08-23 イソキサゾリジン誘導体
JP2018109262A Expired - Fee Related JP6736607B2 (ja) 2012-09-13 2018-06-07 イソキサゾリジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018109262A Expired - Fee Related JP6736607B2 (ja) 2012-09-13 2018-06-07 イソキサゾリジン誘導体

Country Status (28)

Country Link
US (2) US9155747B2 (enExample)
EP (1) EP2895495B1 (enExample)
JP (2) JP2015533801A (enExample)
KR (1) KR101719524B1 (enExample)
CN (2) CN108440637A (enExample)
AR (1) AR092547A1 (enExample)
AU (1) AU2013314539B2 (enExample)
BR (1) BR112015005500B1 (enExample)
CA (1) CA2884705C (enExample)
CL (1) CL2015000610A1 (enExample)
EA (1) EA027034B1 (enExample)
ES (1) ES2672140T3 (enExample)
GE (1) GEP201706708B (enExample)
HK (1) HK1209756A1 (enExample)
IL (1) IL237686A (enExample)
MA (1) MA37927B2 (enExample)
MX (1) MX364865B (enExample)
MY (1) MY182523A (enExample)
NZ (1) NZ705902A (enExample)
PE (1) PE20150675A1 (enExample)
PH (1) PH12015500534B1 (enExample)
PL (1) PL2895495T3 (enExample)
SA (1) SA515360134B1 (enExample)
SG (1) SG11201501902RA (enExample)
TN (1) TN2015000093A1 (enExample)
UA (1) UA116545C2 (enExample)
WO (1) WO2014040837A1 (enExample)
ZA (1) ZA201501691B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140890A1 (es) 2011-03-15 2014-08-05 Chiesi Farma Spa Derivados de isoxazolidina
CA3127373A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN115785188B (zh) * 2022-12-20 2024-06-07 湖南科益新生物医药有限公司 一种布地奈德的制备方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631033A (en) * 1968-05-03 1971-12-28 Lepetit Spa Steroids
US3928326A (en) * 1972-05-19 1975-12-23 Bofors Ab Process for the separation of stereoisomeric mixtures into their components and components obtained hereby
JPS617293A (ja) * 1984-06-20 1986-01-13 Mitsubishi Chem Ind Ltd 新規なコルチコイド誘導体およびその製法
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
US20030176407A1 (en) * 2002-02-20 2003-09-18 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids
WO2005028495A1 (en) * 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
JP2010522233A (ja) * 2007-03-20 2010-07-01 クラヴィス・ファルマ・アーエスアー 抗炎症剤及び抗癌剤であるグルココルチコイドの脂肪酸エステル
WO2011029547A2 (en) * 2009-09-11 2011-03-17 Chiesi Farmaceutici S.P.A. Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
JP2011513303A (ja) * 2008-02-27 2011-04-28 アストラゼネカ・アクチエボラーグ １６アルファ，１７アルファ−アセタールグルココルチコステロイド誘導体およびその使用
WO2012123493A2 (en) * 2011-03-15 2012-09-20 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
WO2012123482A2 (en) * 2011-03-15 2012-09-20 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
WO2013017374A1 (en) * 2011-08-01 2013-02-07 Chiesi Farmaceutici S.P.A. Anti -inflammatory steroids condensed in position 16,17 with pyrrolidine ring

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139369A (en) 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631033A (en) * 1968-05-03 1971-12-28 Lepetit Spa Steroids
US3928326A (en) * 1972-05-19 1975-12-23 Bofors Ab Process for the separation of stereoisomeric mixtures into their components and components obtained hereby
JPS617293A (ja) * 1984-06-20 1986-01-13 Mitsubishi Chem Ind Ltd 新規なコルチコイド誘導体およびその製法
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
US20030176407A1 (en) * 2002-02-20 2003-09-18 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids
WO2005028495A1 (en) * 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
JP2010522233A (ja) * 2007-03-20 2010-07-01 クラヴィス・ファルマ・アーエスアー 抗炎症剤及び抗癌剤であるグルココルチコイドの脂肪酸エステル
JP2011513303A (ja) * 2008-02-27 2011-04-28 アストラゼネカ・アクチエボラーグ １６アルファ，１７アルファ−アセタールグルココルチコステロイド誘導体およびその使用
WO2011029547A2 (en) * 2009-09-11 2011-03-17 Chiesi Farmaceutici S.P.A. Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
WO2012123493A2 (en) * 2011-03-15 2012-09-20 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
WO2012123482A2 (en) * 2011-03-15 2012-09-20 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
WO2013017374A1 (en) * 2011-08-01 2013-02-07 Chiesi Farmaceutici S.P.A. Anti -inflammatory steroids condensed in position 16,17 with pyrrolidine ring

Also Published As

Publication number Publication date
SG11201501902RA (en) 2015-04-29
US9469669B2 (en) 2016-10-18
SA515360134B1 (ar) 2016-07-24
US20140069419A1 (en) 2014-03-13
MX2015002898A (es) 2015-06-03
PH12015500534B1 (en) 2019-01-23
JP2018162270A (ja) 2018-10-18
MA37927B2 (fr) 2021-08-31
CA2884705A1 (en) 2014-03-20
AU2013314539A1 (en) 2015-04-02
CL2015000610A1 (es) 2015-12-04
MX364865B (es) 2019-05-09
PH12015500534A1 (en) 2015-05-04
CN108440637A (zh) 2018-08-24
EP2895495B1 (en) 2018-05-16
AR092547A1 (es) 2015-04-22
EA027034B1 (ru) 2017-06-30
ZA201501691B (en) 2016-10-26
JP6736607B2 (ja) 2020-08-05
KR20150042264A (ko) 2015-04-20
GEP201706708B (en) 2017-07-25
UA116545C2 (uk) 2018-04-10
MA20150350A1 (fr) 2015-10-30
EP2895495A1 (en) 2015-07-22
IL237686A (en) 2017-10-31
MY182523A (en) 2021-01-25
AU2013314539B2 (en) 2018-03-08
CN104619714A (zh) 2015-05-13
PL2895495T3 (pl) 2018-10-31
CA2884705C (en) 2021-04-13
US20150376226A1 (en) 2015-12-31
BR112015005500A2 (pt) 2018-05-22
BR112015005500B1 (pt) 2022-11-22
TN2015000093A1 (en) 2016-06-29
EA201590390A1 (ru) 2015-08-31
KR101719524B1 (ko) 2017-03-24
PE20150675A1 (es) 2015-05-20
US9155747B2 (en) 2015-10-13
NZ705902A (en) 2018-04-27
ES2672140T3 (es) 2018-06-12
HK1209756A1 (en) 2016-04-08
WO2014040837A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
CN114426568B (zh) 2-氧代-3-吡咯烷基丙腈类化合物及其药物组合物和用途
JP6736607B2 (ja) イソキサゾリジン誘導体
TWI494318B (zh) 異唑啶衍生物
US10280193B2 (en) Isoxazolidine derivatives
US8835412B2 (en) Isoxazolidine derivatives
HK1259584A1 (en) Isoxazolidine derivatives
US8710037B2 (en) Pyrrolidine derivatives, pharmaceutical compositions containing the same, and methods of using the same
Shim et al. Ginsenoyne C, a polyacetylene isolated from Panax Ginseng inhibit inflammatory mediators via regulating extracellular regulated kinases signaling
HK1189599A (en) Isoxazolidine derivatives
HK1196969A (en) Anti-inflammatory steroids condensed in position 16, 17 with pyrrolidine ring
HK1166085B (en) Isoxazolidine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180118

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180213